New drug doubles 1-year survival in pancreatic cancer trial
medicalxpress - Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.
AI Summary: A Phase 3 study showed a novel agent markedly lengthened survival for people with metastatic pancreatic cancer, roughly doubling one-year survival versus standard care. The results, from the RASolute 302 program evaluating daraxonrasib/Revolution Medicines’ approach, represent an uncommon advance in a stubbornly lethal disease and could change treatment standards pending regulatory review.
- Clinicians celebrate landmark KRAS win; cautious optimism prevails (7)
- Daraxonrasib Phase 3: drug doubles one-year survival (5)
- Market scramble: Revolution Medicines' fundraising and buyout buzz (3)
- Other pancreatic research, methods and early-stage KRAS studies (5)
- All Other Stories
Clinicians celebrate landmark KRAS win; cautious optimism prevails
Daraxonrasib Phase 3: drug doubles one-year survival
Market scramble: Revolution Medicines' fundraising and buyout buzz
Other pancreatic research, methods and early-stage KRAS studies
All Other Stories
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
FDA grants early access to experimental pancreatic cancer drug / 29 days
FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 46 hrs
FDA to revisit Atara/Pierre Fabre cell therapy approval for rare lymphoma / 22 days
FDA advisory panel rejects camizestrant after SERENA‑6 results / 29 days
Phase 2 POLAR reports pembrolizumab plus olaparib outcomes in HRD pancreatic cancer / 2 months
Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 3 hrs
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 15 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Wildlife, Hearing Loss, Animal Health, Healthcare and look for the RSS link.
StackHealth Time Machine